Entrada Therapeutics FY2023 net loss $6.7M, cash $352M; DMD Phase 1 data on track

Entrada Therapeutics, Inc.

Cash, equivalents and marketable securities $352.0M as of Dec 31, 2023, up from $188.7M; runway through Q2 2026.
Collaboration revenue $129.0M full year (Vertex deal); net loss narrowed to $6.7M from $94.6M in 2022.
Completed dosing first three cohorts of ENTR-601-44 Phase 1 for DMD; data readout H2 2024.
Regulatory applications expected Q4 2024 for global Phase 2 of ENTR-601-44 and ENTR-601-45.
Promoted Nathan Dowden to President & COO; appointed Kevin Healy (SVP Regulatory) and Marie Rosenfeld (SVP Clinical Ops).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Entrada Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss was $6.7 million for the full year of 2023.

Period: the year ended December 31, 2023
Net income: Net loss was $6.7 million for the full year of 2023
Result: reported results

Exact text from the filing

On March 13, 2024, Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2023 and other corporate updates.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001689375-24-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.